Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return...
AMD and IBM's partnership to develop hybrid quantum-classical computing systems is a major catalyst, targeting commercial viability in quantum computing. I reiterate my Strong Buy rating on AMD, expecting it to benefit earlier from GPU and FPGA integration into IBM's quantum systems. IBM's quantum backlog is small now, but the partnership positions it for long-term growth in a $130B quantum mar...
International Business Machines Corporation delivered its strongest revenue growth in three years, with Q2 revenues up 7.65% YoY and significant margin expansion. Despite Q2 outperformance, IBM only reiterated full-year revenue guidance, disappointing some investors and triggering a post-earnings selloff. Profitability outlook remains robust with analysts raising FY1 EPS estimates. However, IBM...
IBM and AMD are partnering to develop next-generation computing architectures that integrate IBM's quantum systems with AMD's AI-specialized chips. The move could position both the tech giant and chipmaker as key infrastructure players, as they look to regain ground after falling behind on the generative AI boom.
Companies aim to merge AI accelerators, quantum computers, and high-performance computing to help solve a wide range of the world's most difficult problems YORKTOWN HEIGHTS, N.Y. and AUSTIN, Texas , Aug. 26, 2025 /PRNewswire/ -- Today, IBM (NYSE: IBM) and AMD (NASDAQ: AMD) announced plans to develop next-generation computing architectures based on the combination of quantum computers and high-...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.